Clinical trials
DMMR Colorectal Cancer clinical trials
Below are recruiting dmmr colorectal cancer clinical trials, each written for real people, not researchers. We’re tracking 82 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04014530RecruitingPhase 1/Phase 2
Testing pembrolizumab plus ataluren for metastatic dMMR or pMMR cancer
This early-phase trial tests pembrolizumab combined with ataluren for people with metastatic colorectal cancer that has either dMMR or pMMR, and for metastatic dMMR endometrial cancer. The goal is to see whether this combination can shrink tumors or improve outcomes for cancers with specific mismatch repair (MMR) features.
Amsterdam, North HollandAges 18 years+ - NCT06176885RecruitingPhase 2
Immunotherapy plus chemo and targeted therapy for MSS colorectal cancer
This trial tests adding immunotherapy to standard chemotherapy and targeted therapy for people with metastatic colorectal cancer that is MSS (microsatellite stable) and cannot be removed with surgery. It aims to see if this combination helps shrink tumors and improve outcomes.
Jinhua, ZhejiangAges 18–75 - NCT06218810RecruitingPhase 2
Combination therapy for advanced MSS, RAS-mutated colorectal cancer
This trial tests a new combination of three medicines for people with a certain type of advanced colorectal cancer that has not been treated before. It aims to see if adding an immunotherapy drug (Cadonilimab) to standard chemotherapy and a targeted therapy (Bevacizumab) can help shrink tumors and delay disease progression.
ShanghaiAges 18–75 - NCT06566755RecruitingPhase 3
New drug combo for a common type of colorectal cancer
This trial tests a combination of a new immunotherapy (cadonilimab) with standard chemotherapy (capecitabine, oxaliplatin) and bevacizumab for people with metastatic colorectal cancer that has a RAS mutation or is located on the right side of the colon. The goal is to see if this combination works better than the current standard of care as a first treatment.
Shenyang, LiaoningAges 18–75 - NCT06520683RecruitingPhase 3
Immunotherapy after surgery for high-risk stage II colorectal cancer
This trial tests whether a drug called an immune checkpoint inhibitor (PD-1 blocker) can help lower the risk of cancer returning after surgery. It is for people with a specific type of colorectal cancer (dMMR or MSI-H) that had certain high-risk features.
Guangzhou, GuangdongAges 18–80 - NCT07627191RecruitingEarly Phase 1
GLP-1 drug plus standard chemo for first-line advanced cancers
This trial tests whether adding a GLP-1 receptor agonist (a drug used for diabetes and weight loss) to standard chemotherapy can help people with advanced pancreatic, colorectal, or liver cancer. It is for people who have not yet started treatment for their metastatic disease and have a BMI of 25 or higher.
Tucson, ArizonaAges 18–99 - NCT07551596RecruitingPhase 2
Two immunotherapy drugs for colorectal cancer with residual disease
This trial tests a combination of two immunotherapy drugs to see if they can stop colorectal cancer from returning after standard treatment. It is for people who still have cancer DNA in their blood after surgery and/or chemotherapy, which means they are at high risk of the cancer coming back.
New Orleans, LouisianaAges 18 years+ - NCT06613165Recruiting
Short vs long treatment for stage II-III rectal cancer with dMMR
This trial tests how long you need a PD-1 immunotherapy before surgery for a specific type of rectal cancer (dMMR/MSI-H). It looks at whether a shorter or longer course works best. This could mean fewer side effects and a quicker path to surgery.
Xi'an, ShaanxiAges 18–80 - NCT07446322RecruitingPhase 2
Study of a new drug plus standard chemo for advanced colorectal cancer
This trial tests if adding the experimental drug pelareorep to standard chemotherapy (FOLFIRI) and bevacizumab can help people with a specific type of advanced colorectal cancer that has a RAS mutation and is not caused by high microsatellite instability. You may be able to join if you've already tried one type of chemotherapy and it stopped working or you couldn't tolerate it.
Homewood, AlabamaAges 18 years+ - NCT06282445RecruitingPhase 2
Combination therapy for first-line metastatic colorectal cancer
This trial tests whether adding the immunotherapy drug adebrelimab to standard chemotherapy plus bevacizumab can help people with a specific type of metastatic colorectal cancer that cannot be removed by surgery. It is for patients whose tumors are microsatellite stable (MSS) or have normal mismatch repair (pMMR).
Jinhua, ZhejiangAges 18–75 - NCT07353645RecruitingPhase 1/Phase 2
KRAS vaccine for colorectal and pancreatic cancer after surgery
This trial tests a new vaccine that targets KRAS mutations in patients with colorectal or pancreatic cancer after surgery and chemotherapy. The goal is to see if the vaccine can help prevent the cancer from coming back.
Nanjing, JiangsuAges 18–75 - NCT07327489Recruiting
Live tumor biopsy study to predict immunotherapy response
This trial studies how well immunotherapy might work by analyzing fresh tumor biopsies. It may help predict which treatments are best for your cancer.
Fort Smith, ArkansasAges 18 years+ - NCT07321106RecruitingPhase 1
CBI-1214 for advanced colorectal cancer
This trial tests a new drug called CBI-1214, which is designed to help your immune system attack cancer cells. It is for people with advanced colorectal cancer that has not responded to other treatments.
Phoenix, ArizonaAges 18 years+ - NCT06698757RecruitingPhase 2
Testing different cycles of sintilimab before surgery for colorectal cancer
This trial tests how many cycles of the immunotherapy drug sintilimab given before surgery help treat colorectal cancer that is mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H). It is for locally advanced cancer that has not spread to other parts of the body.
Zheng'zhou, HenanAges 18–75 - NCT07213570RecruitingPhase 2
Second-line regorafenib for advanced RAS-mutant colorectal cancer
This trial tests regorafenib as a second-line treatment for people with advanced colorectal cancer that has a RAS mutation. It aims to see if this targeted therapy can help when the first treatment stopped working.
Naples, ItalyAges 18 years+ - NCT06992258RecruitingPhase 2
Comparing two drug combinations for advanced colorectal cancer
This trial tests whether adding TAS-102 to fruquintinib works better than fruquintinib alone for people with advanced colorectal cancer that has stopped responding to other treatments.
New Haven, ConnecticutAges 18 years+ - NCT06974110RecruitingPhase 1
Study of a new drug for advanced solid tumors with MSI-H or dMMR
This trial tests an oral medication called MOMA-341 in people with advanced solid tumors that have high microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR). It aims to see if the drug can help when prior immunotherapy hasn't worked or isn't available.
Phoenix, ArizonaAges 18 years+ - NCT06959589Enrolling by invitationPhase 2
Combination therapy for KRAS G12C mutated colorectal cancer
This trial tests a new drug combination (IBI351, cetuximab, and FOLFIRI) as first treatment or as a second treatment after standard chemotherapy for people with KRAS G12C mutated colorectal cancer that has spread. The goal is to see if it works well and is safe.
Hangzhou, ZhejiangAges 18–75 - NCT06959550RecruitingPhase 2
Ivonescimab for previously treated metastatic colorectal cancer
This trial tests a new drug called ivonescimab, which is a bispecific antibody that targets both PD-1 and VEGF. It is for people with metastatic colorectal cancer who have already tried standard treatments and may or may not have received immunotherapy before, depending on their tumor type.
Houston, TexasAges 18 years+ - NCT05771181RecruitingPhase 2
Test vitamin E plus two cancer drugs for metastatic colon cancer
This trial tests whether adding vitamin E to two cancer medicines (fruityquintinib and tislelizumab) can work better in people with metastatic colorectal cancer that is mismatch-repair stable (MSS). It may help if your cancer has grown despite standard treatment, and you can meet the study’s safety and blood/organ requirements.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06948448RecruitingPhase 2
New treatment for advanced colorectal cancer with PD-L1 biomarker
This trial tests a new drug (ONO-4578) combined with standard chemotherapy and immunotherapy for people with advanced colorectal cancer that has not been treated before and has a specific marker called PD-L1. The goal is to see if this combination works better than the usual treatment.
Phoenix, ArizonaAges 18 years+ - NCT06936527Enrolling by invitationPhase 1/Phase 2
XS-03 plus chemotherapy and bevacizumab for metastatic colorectal cancer with RAS mutation
This trial tests an experimental drug called XS-03 combined with standard chemotherapy (FOLFOX or FOLFIRI) plus a targeted therapy (bevacizumab) for people with metastatic colorectal cancer that has a RAS mutation. The goal is to see if adding XS-03 helps shrink tumors or slows cancer growth better than current treatments.
BeijingAges 18–75 - NCT06903858RecruitingPhase 2
Toripalimab plus celecoxib for dMMR/MSI-H colorectal cancer
This trial tests whether combining toripalimab (an immunotherapy) with celecoxib (an anti-inflammatory drug) can shrink locally advanced colorectal tumors that have specific genetic features (dMMR or MSI-H). It aims to help people who haven't had any prior treatment for their colorectal cancer.
Guangzhou, GuangdongAges 18 years+ - NCT06714357RecruitingPhase 2
Valproic Acid to Boost Anti-EGFR in Colorectal Cancer
This trial tests whether adding valproic acid to standard anti-EGFR plus irinotecan can stop or reverse resistance in metastatic colorectal cancer. It is for patients who previously responded well to an anti-EGFR drug and then progressed.
Caserta, CEAges 18 years+
Hear when a new DMMR Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for dmmr colorectal cancer?
- Yes. Clin2 currently lists 82 recruiting dmmr colorectal cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a dmmr colorectal cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a dmmr colorectal cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.